ExpreS2ion strengthens its organization to further accelerate its pipeline project development
Hørsholm, Denmark, January 11, 2021 – ExpreS2ion Biotech Holding AB hereby announces that its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is reorganizing the company’s top management to reflect its increased strategic focus on pipeline development. Several appointments within research and development will ensure the advancement of ExpreS2ion’s development projects towards clinical investigations, with the first fully controlled project being the unique Her2-cVLP breast cancer project. This project will be in-licensed from ExpreS2ion’s joint venture AdaptVac ApS (“AdaptVac”) and